Answers are grounded in this paper and cite their sources.
The new liquid crystalline heteronuclear complexes Cu(II) 1a and Pd(II) 1b with a non-mesogenic ferrocene-containing β-enaminoketone L1 of the formula C5H5FeC5H4 -C6H4-NH-C2H2-(CO)-C6 H4OC12H25, showing monotropic nematic and smectic A phases, are studied. The ortho-palladated Cl-bridged dimeric complex 3 with a non-mesogenic ferrocene-containing Schiff's base L2 of the formula C5H5FeC5H4 -C6H4-N=CH-C6H4OC10H21, forming a stable smectic A phase, has been synthesized. The novel mixed-ligand heteronuclear complexes 4–7 have been obtained by treatment of the ortho-palladated complex 3 with appropriate ligands. Some of the resulting products exhibit the rather low-melting (below 100 [ddot]C) smectic A phases. Structures of the compounds are studied by elemental analysis, 1H and 13C NMR, and ESR spectroscopies.
No takes yet. Share an insight, caveat, or question.
Kadkin et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: